Evidence map›Paper›PMID 30099641›Full record

ArticleInternational orthopaedics2019

Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.

Shinji Tsukamoto, Andreas F Mavrogenis, Giulio Leone, Alberto Righi, Manabu Akahane, Piergiuseppe Tanzi, Akira Kido, Kanya Honoki, Yasuhito Tanaka, Davide Maria Donati and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in International orthopaedics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Shinji TsukamotoDepartment of Orthopaedics, Nara Medical University, Nara, Japan. shinji104@mail.goo.ne.jp.
Andreas F MavrogenisFirst Department of Orthopaedics, National and Kapodistrian University of Athens, School of Medicine, 41 Ventouri Str., 15562, Athens, Greece. afm@otenet.gr.ORCID http://orcid.org/0000-0003-0807-0719
Giulio LeoneDepartment of Orthopaedics, San Gerardo Hospital, Monza, Italy.
Alberto RighiDepartment of Pathology, Istituto Ortopedico Rizzoli, Bologna, Italy.
Manabu AkahaneDepartment of Public Health, Health Management, and Policy, Nara Medical University, Nara, Japan.
Piergiuseppe TanziDepartment of Orthopaedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.
Akira KidoDepartment of Orthopaedics, Nara Medical University, Nara, Japan.
Kanya HonokiDepartment of Orthopaedics, Nara Medical University, Nara, Japan.
Yasuhito TanakaDepartment of Orthopaedics, Nara Medical University, Nara, Japan.
Davide Maria DonatiDepartment of Orthopaedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.
Costantino ErraniDepartment of Orthopaedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. costantino.errani@ior.it.
Nara Medical University · JPIstituto Ortopedico Rizzoli · ITAzienda Ospedaliera San Gerardo · ITNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere are conflicting reports on the effect of denosumab on lung metastases in patients with giant cell tumor (GCT) of bone. To address these reports, we performed this study to determine if denosumab prevents lung metastasis and to evaluate univariate and multivariate predictors for lung metastases in these patients. MATERIALS AND

methodsWe retrospectively studied 381 GCT patients with surgery alone and 30 GCT patients with surgery and denosumab administration. The median follow-up was 85.2 months (IQR, 54.2-124.4 months). We evaluated lung metastases and local recurrences, univariate and multivariate predictors for lung metastases, response, and adverse events of denosumab administration.

resultsThe occurrence of lung metastases was similar (surgery alone 4.7%, 18 patients; denosumab administration 3.3%, 1 patient); however, the occurrence of local recurrences was significantly higher in the patients with denosumab administration. Denosumab administration was not an important predictor for lung metastases; Campanacci stage and type of surgery were the only univariate predictors for lung metastases, and type of surgery and local recurrence were the only multivariate predictors for lung metastases. Histology showed viable tumour in all tumor specimens of the patients with denosumab administration.

conclusionDenosumab does not decrease the risk of lung metastases in patients with bone GCT; the only important predictors for lung metastases in these patients are type of surgery and local recurrence. However, because the number of patients with lung metastases was small for a multivariate analysis, the possibility of denosumab's effect could not be completely eliminated.

Indexed as

AdultBone Density Conservation AgentsBone NeoplasmsDenosumabFemaleGiant Cell Tumor of BoneHumansLung NeoplasmsMaleRetrospective StudiesBone Density Conservation AgentsDenosumabDenosumabGiant cell tumour of boneLungsMetastasis

Identifiers

PMID30099641
OpenAlexW2887466929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.